Most children over I year old with disseminated neuroblastoma will succumb to resistant disease. A prominent fibrous stromal background to tumour infiltrate in the bone marrow, both at diagnosis and subsequently, is characteristic of disseminated neuroblastoma. How much of this fibrous component is reactive and how much a product of the tumour itself is still unknown. With current histological techniques, it is difficult to determine whether residual tissue in marrow or primary site still contains viable tumour after chemotherapy. The presence of clonal karyotypic abnormalities characteristic of neuroblastoma in cells from residual scar tissue would provide evidence that viable tumour cells remained. We describe a child with stage IV neuroblastoma in whom intensive cytogenetic investigation of bone marrow and residual primary tissue was carried out immediately prior to myeloablative treatment and autologous marrow rescue.
Case report
Stage IV neuroblastoma was diagnosed in a 7 year old boy: this was based on infiltration of bone marrow with non-haemopoietic cells detected in marrow aspirate and a trephine biopsy specimen, a raised urinary vanillylmandelic acid (VMA) concentration, multiple Accepted for publication 27 (100 U/ml), and streptomycin (100 Mg/ml). Long term cultures were subcultured and harvested using conventional trypsinisation methods. Metaphase preparations were prepared after treatment with colcemid (0-08 pg/ml) and were stained using standard Gbanding. This study provides direct evidence of the presence of viable tumour cells in a shrunken primary tumour and raises the possibility that similarly viable cells may be present in the residual fibrous tissue so often found in the bone marrow. When the primary tumour is removed in patients with neuroblastoma, cytogenetic investigation of any biopsy tissue should be routinely performed. Information from such studies may make unequivocal the often ambiguous remission state of many children with disseminated neuroblastoma, permit better evaluation of their response to treatment, and provide the basis for a rational approach to further treatment. This approach could be extended to patients with other solid tumours in whom "second look" surgery is performed.
